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Background: Precise diagnostics of inflammatory bowel disease (IBD) and identification of potentially more
aggressive phenotypes of Crohn’s disease (CD) is urgently needed. The aim of our prospective study was to assess
the relationship between serum anti-OmpC IgA (Outer membrane protein C), anti-GP2 (anti-glycoprotein 2) IgG and
anti-GP2 IgA antibodies with IBD and their association with complicated forms of CD.
Methods: The study included 86 patients with CD, 25 patients with UC and 45 controls, blood donors. In CD
group, 24/86 (28%) had B1 phenotype, 20/86 (23%) B2, 13/86 (15%) B3 and 29/86 (34%) B2 + B3. L1 involvement
was present in 13/86 (15%), L2 in 13/86 (15%), L3 in 60/86 (70%). Serum anti-OmpC IgA, anti-GP2 IgG and IgA
antibodies were investigated by means of ELISA. The data obtained were tested statistically by means of descriptive
statistics, non-paired t-test, Mann-Whitney rank sum test, Spearman rank order correlation and Pearson product
moment correlation using SigmaStat software.
Results: Anti-OmpC IgA were noted to be significantly higher in CD (median 32.6, inter-quartile range (IQR) 18.9-60.7)
compared to the controls (median 18.3, IQR 11.1-23.1), p < 0.001. Anti-GP2 IgG were significantly higher in CD (median
13.9, IQR 8.6-25.6) compared to the controls (median 8.0, IQR 4.7-10.8), p < 0.001. Anti-GP2 IgA were significantly higher
in CD (median 20.1, IQR 9.1-40.4) compared to the controls (median 9.8, IQR 5.6-16.9), p < 0.001. Significant difference
was found in anti-OmpC IgA between UC (median 26.2, IQR 20.2-36.4) and the controls (median 18.3, IQR 11.1-23.1),
p < 0.001. In CD anti-OmpC IgA were significantly higher in B2 compared to B1: p = 0.041 and in B2 + B3 compared to
B1: p = 0.036. Anti-GP2 IgA were significantly higher in B2 + B3 compared to B1: p = 0.009 and in B3 compared to B1:
p = 0.029. In CD there was a significant difference in anti-OmpC IgA between patients with surgery and without surgery,
p = 0.005.
Conclusions: We have confirmed association between anti-OmpC IgA and IBD (CD and UC) and an association
between anti-GP2 (IgG and IgA) and CD. Patients with complicated forms of CD have significantly higher levels
of anti-OmpC IgA and anti-GP2 IgA.
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Inflammatory bowel disease (IBD) with its increasing
incidence represents an extraordinary problem in the
developed countries. Precise diagnostics of IBD, differen-
tiation of ulcerative colitis (UC) vs. Crohn’s disease (CD)
and recognition of potentially more aggressive pheno-
types of CD from the benign ones is urgently needed.
The opportunity to identify subgroups of patients, who
are more likely to develop complicated B2 (stricturing)
and/or B3 (penetrating) and/or P (perianal) form of CD,
which would be followed by an appropriate early thera-
peutic intervention, should prevent surgery, need of
hospitalization and could have favourable personal and
economical impacts as well [1-5]. Large intestinal micro-
biota play an important role in the etiopathogenesis of
CD [6,7]. Recent studies have shown, that there is an
association between disease onset, location, behaviour
and serologic markers, from which some do reflect
contribution of large intestinal microbiota to the devel-
opment of CD [8-16]. A study performed by Papp et al.
showed that the presence of auto-antibodies (including
anti-OmpC) is associated with more complicated behav-
iour of the disease and the need for surgery in CD patients
[11]. Similarly Mow et al. revealed that patients with
anti-OmpC antibodies were increasingly likely to have
internal perforating disease and at greater risk of requiring
small bowel surgery [13]. Dubinsky et al. performed an
important study within the pediatric population and
discovered that if a child was positive in ≥1 of the anti-
bodies tested (including anti-OmpC and ASCA), the
probability of progression to internal penetrating and/
or stricturing disease during the follow-up was higher,
in comparison to those children who were not found to be
positive for these antibodies [16]. Pancreatic antibodies
have been isolated more recently and association mainly
with CD patients has been shown [14].
The aim of our prospective study was to assess the
relationship between anti-OmpC IgA (Outer membrane
protein C), anti-GP2 (anti-glycoprotein 2) IgG and anti-
GP2 IgA antibodies with IBD and their possible associ-
ation with complicated forms of CD.
Methods
Patients
A total of 86 consecutive patients with CD (37 men, 49
women, aged 20–79, mean 43 ± 14), 25 patients with UC
(9 men, 16 women, aged 20–74, mean 44 ± 16) and 45
controls, healthy blood donors (24 men, 21 women, aged
22–60, mean 41 ± 11) were enrolled into the prospective
study. In the CD group 24/86 (28%) patients had
nonstricturing-nonpenetrating (B1) form of CD, 20/86
(23%) stricturing (B2) phenotype, 13/86 (15%) penetrating
(B3) phenotype and 29/86 (34%) stricturing + penetrating
(B2 + B3) phenotype according to Montreal classification(ref.: 2 Silverberg). None of these patients had isolated
perianal CD. Small bowel involvement (L1) was present in
13/86 (15%), colonic involvement (L2) in 13/86 (15%),
ileocolonic involvement (L3) in 60/86 (70%), none of
the CD patients had isolated involvement of the upper
gastrointestinal tract (L4).
The duration of CD was 0–39 years, mean 15 ± 9; the
duration of UC was 3–47 years, mean 14 ± 11. A total
of 10 patients with CD were not on any therapy, 26 patients
were on 5-aminosalicylates and 50 had immunosuppressive
therapy (+/− corticosteroids, methotrexate, azathio-
prine, anti-TNF therapy). Within the UC patient cohort
1 patient was not on any treatment, 14 patients were re-
ceiving 5-aminosalicylates and 10 patients were treated
with immunosuppresive therapy at the time of their blood
tests.
The extraintestinal manifestations in patients with CD
included musculoskeletal, dermatological, ocular, renal
and hepatopancreatobiliary complications.
Serum antibodies
Serum IgA anti-OmpC antibodies were investigated by
means of ELISA (purchased from QUANTA Lite TM
OMP Plus, INOVA Diagnostics, San Diego, USA). Values
<20 U/mL were assessed as negative, values >25 U/mL
were considered to be positive according to the manufac-
turer. Anti-GP2 IgG and IgA antibodies were investigated
by means of ELISA (Generic Assays, Berlin, Germany),
with negative results <15 U/mL and positive results
>20 U/mL. The investigation of antibodies in the
peripheral blood was performed between year 2010 and
2012; all patients included into the study have remained
under the regular surveillance.
Statistical analysis
Data obtained were tested statistically by means of de-
scriptive statistics, non-paired t-test, Mann-Whitney
rank sum test, Spearman rank order correlation and
Pearson product moment correlation using SigmaStat
software (Version 3.1, Jandel Corp., Erkrath, Germany).
Ethical issues
All patients included in the study were notified with the
necessary information and provided informed consent via
a signed form. The project was approved by the Joint
Ethical Committee (Charles University in Praha, Faculty
of Medicine at Hradec Kralove & University Teaching
Hospital Hradec Kralove). For all data obtained, all per-
sonal identification information was removed in compli-
ance with the Czech laws for protection of confidentiality.
Results
Serum anti-OmpC IgA were significantly higher in
CD (median 32.6, inter-quartile range (IQR) 18.9-60.7)
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p < 0.001. Serum anti-GP2 IgG were also significantly
higher in CD (median 13.9, IQR 8.6-25.6) compared to the
controls (median 8.0, IQR 4.7-10.8), p < 0.001. Anti-GP2
IgA were significantly higher in CD (median 20.1, IQR
9.1-40.4) compared to the controls (median 9.8, IQR
5.6-16.9), p < 0.001, see Figure 1.
In CD there was a significant correlation between anti-
GP2 IgG and anti-GP2 IgA values (r = 0.565, p < 0.001),
between anti-GP2 IgG and anti-OmpC IgA values
(r = 0.358, p < 0.001), between anti-GP2 IgA and anti-
OmpC IgA values (r = 0.385, p < 0.001).
Table 1 provides percentige of abnormal values and
values within normal ranges of serum anti-OmpC IgA,
anti-GP2 IgG and anti-GP2 IgA in the controls, patients
with CD and patients with UC.
Table 1 shows sensitivity, specificity, negative and positive
predictive values of serum anti-OmpC IgA, anti-GP2 IgG
and anti-GP2 IgA antibodies in each group of patients.
Descriptive statistics for each CD phenotype are given
in Table 2. In CD Anti-OmpC IgA were significantly
higher in B2 phenotype compared to B1: p = 0.041 and
in B2 + B3 phenotype compared to B1: p = 0.036. Anti-
GP2 IgA were significantly higher in B2 + B3 phenotype
compared to B1: p = 0.009 and in B3 phenotype com-
pared to B1: p = 0.029. Trend towards statistically higher
levels of anti-GP2 IgG was observed in B2 + B3 when
compared to B1 phenotype: p = 0.057.
Descriptive statistics for ileal (L1) CD, colonic (L2) CD
and ileocolonic (L3) CD are provided in Table 3. Patients
with L2 involvement had statistically significantly lower
levels of anti-OmpC antibodies than patients with L3
involvement: p = 0.042. No other significant difference
depending on location was found in anti-OmpC IgA,
anti-GP2 IgG and anti-GP2 IgA.Figure 1 Anti-GP2 IgG, anti-GP2 IgA and anti-OmpC IgA antibodies in
range. Asterisk (*) means statistically significant difference (p < 0.001) in relStatistically significant difference was found in anti-
OmpC IgA between UC (median 26.2, IQR 20.2-36.4)
and the controls (median 18.3, IQR 11.1-23.1), p < 0.001,
see Figure 1.
No statistically significant difference was found in
serum anti-GP2 IgG levels between UC and the controls
(p = 0.342) and in serum anti-GP2 IgA levels between
UC and the controls (p = 0.138).
In UC there was a significant correlation between anti-
GP2 IgA and anti-OmpC IgA values (r = 0.554, p = 0.004).
No correlation was identified between anti-GP2 IgA and
anti-GP2 IgG values, between anti-GP2 IgG and anti-
OmpC IgA values.
No relationship was found between age and anti-
OmpC IgA, anti-GP2 IgG, anti-GP2 IgA in CD patients
and between age and anti-OmpC IgA in UC patients.
In CD there was no statistically significant difference
in anti-OmpC IgA, anti-GP2 IgG, anti-GP2 IgA anti-
bodies between groups of patients, who were diagnosed
with CD ≤17 years (13/86, 15%), >17 and ≤40 years (64/86,
75%) and >40 years (9/86, 10%).
Weak but statistically significant negative correlation
between the age of onset and anti-OmpC IgA was found
in CD (r = −0.225; p = 0.037). No relationship was revealed
between the duration of CD and value of anti-OmpC IgA,
anti-GP2 IgG, anti-GP2 IgA antibodies respectively.
There were no differences in anti-OmpC IgA, anti-
GP2 IgG, anti-GP2 IgA antibodies between patients with
and without family history of IBD and with and without
perinal disease in CD patients.
A trend towards statistically significant difference
was revealed in anti-GP2 IgA between patients with
an extraintestinal manifestation of CD (median 43.1,
IQR 12.2-51.4) and without an extraintestinal mani-
festation of CD (median 17.5, IQR 8.8-34.4), p = 0.05.controls, patients with CD and UC: median and inter-quartile
evant antibody between controls and CD/UC respectively.
Table 1 Abnormal values and values within normal ranges of serum anti-OmpC IgA (>25U/mL vs. <20U/mL), anti-GP2
IgG (>20U/mL vs. <15U/mL) and anti-GP2 IgA (>20U/mL vs. <15U/mL) in controls, CD patients and UC patients
controls CD UC
Anti-OmpC IgA >25U/mL 8/45 (18%) 53/86 (62%) 13/25 (52%)
Anti-OmpC IgA <20U/mL 26/45 (58%) 22/86 (26%) 6/25 (24%)
Anti-GP2 IgG >20U/mL 1/45 (2%) 27/86 (31%) 4/25 (16%)
Anti-GP2 IgG <15U/mL 42/45 (93%) 49/86 (57%) 21/25 (84%)
Anti-GP2 IgA >20U/mL 8/45 (18%) 43/86 (50%) 2/25 (8%)
Anti-GP2 IgA <15U/mL 33/45 (73%) 35/86 (41%) 21/25 (84%)
Sens/Spec/NPV/PPV of anti-OmpC IgA [%] 71/76/54/87 68/76/81/62
Sens/Spec/NPV/PPV of anti-GP2 IgG [%] 36/98/47/96 16/98/67/80
Sens/Spec/NPV/PPV of anti-GP2 IgA [%] 55/80/49/84 9/80/61/20
Sens: sensitivity, spec: specificity, NPV: negative predictive value, PPV: positive predictive value.
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anti-OmpC IgA or anti-GP2 IgG between patients with
and without an extraintestinal manifestation of CD
(p = 0.528; p = 0.588).
Significant difference in anti-GP2 IgA was found between
CD patients who were either not on any therapy or were
treated with 5-aminosalicylates only (median 11.9, IQR 7.3-
33.9) and CD patients treated with +/− corticosteroids,
methotrexate, azathioprine, anti-TNF therapy (median 25.6,
IQR 11.7-46.8), p = 0.047. In CD there was no difference
noted in anti-OmpC IgA, anti-GP2 IgG, anti-GP2 IgA
antibodies between patients with anti-TNF and without
anti-TNF therapy.
No relationship was revealed between disease onset,
disease duration and anti-OmpC IgA, anti-GP2 IgG,
anti-GP2 IgA antibodies in UC patients.Table 2 Descriptive statistics (values of antibodies in U/mL)
for each CD phenotype: B1: nonstricturing-nonpenetrating
behaviour, B2: stricturing behaviour, B3: penetrating
behaviour (Montreal classification)
Parameter Median Inter-quartile range
B1 anti-OmpC IgA 21.0 16.0-42.5
anti-GP2 IgG 11.9 7.0-15.5
anti-GP2 IgA 11.1 6.3-24.5
B2 anti-OmpC IgA 40.9 25.1-54.8
anti-GP2 IgG 18.0 8.3-48.1
anti-GP2 IgA 16.6 6.4-37.3
B3 anti-OmpC IgA 33.2 17.7-74.6
anti-GP2 IgG 11.9 8.7-20.4
anti-GP2 IgA 30.5 13.3-48.2
B2 + B3 anti-OmpC IgA 38.7 23.5-67.3
anti-GP2 IgG 16.1 10.5-33.3
anti-GP2 IgA 21.6 14.8-65.7Discussion
Mechanism of IBD development is still poorly under-
stood, however it is generally accepted, that pathogenesis
of IBD involves an inappropriate response of the muco-
sal immune system towards large intestinal microbiota
in genetically susceptible individuals [17].
Until now, no exact bacterial species, which might be
closely associated with the development of IBD, have been
described. The main explanation could be, that only
approximately 50% of intestinal bacteria are culturable
[18]. Kotlowski et al. combined in their study culture-
independent methods with bacterial culture and found
out, that the tissue of IBD patients contained 3–4 logs
higher amounts of bacteria from Enterobacteriaceae family
and the difference between IBD patients and the controls
was statistically significant. Also Escherichia coli genotypes
B2 and D (which are associated with more virulent strains)
were more prevalent in patients with IBD [19].
Anti-OmpC antibodies are aimed at porins, proteins
embedded in the outer membrane of Escherichia coli
[20]. Positivity of anti-OmpC antibodies in patients withTable 3 Descriptive statistics (values of antibodies in U/mL):
L1: involvement of terminal ileum, L2: colonic involvement,
L3: ileocolonic involvement (Montreal classification)
Median Inter-quartile range
L1 anti-OmpC IgA 27.8 17.7-49.2
anti-GP2 IgG 11.5 9.6-33.3
anti-GP2 IgA 22.3 7.4-39.6
L2 anti-OmpC IgA 18.8 15.4-32.7
anti-GP2 IgG 10.6 7.7-14.9
anti-GP2 IgA 22.2 6.6-39.0
L3 anti-OmpC IgA 38.2 22.4-63.9
anti-GP2 IgG 14.8 7.6-29.2
anti-GP2 IgA 20.1 10.5-42.8
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Anti-OmpC antibodies were found in 55% of adult CD
patients [21], 24% of pediatric CD patients, 11% of
pediatric UC patients and 5% of the controls [22]. We
found positivity of serum anti-OmpC IgA antibodies in
62% adult CD patients and in 52% adult UC patients,
both results are significantly higher when compared to the
controls. Eventhough immunoreactivity of anti-OmpC to
pANCA antibodies was described [23], and therefore we
could hypothesize anti-OmpC seropositivity in UC patients,
our results do confirm closer relationship of anti-OmpC
antibodies with CD than with UC. The above mentioned
study carried out by Kotlowski et al. [19] with the com-
bination of well-known specific association of adherent-
invasive Escherichia coli with ileal mucosa in CD [24]
explain our results.
Patients with complicated forms of CD - stricturing
(B2) and stricturing + penetrating (B2 + B3) phenotype
had significantly higher serum levels of anti-OmpC anti-
bodies when compared to those with nonstricturing-
nonpenetrating (B1) phenotype in our study and patients
with ileocolonic involvement (L3) had higher levels of
anti-OmpC compared to patients with isolated colonic
(L2) involvement. Association of anti-OmpC antibodies
with complicated forms of CD - internal penetrating
disease (B3) and need for surgery has been published by
other authors [10,13,14]. Dubinski et al. confirmed, that
serum anti-OmpC antibodies are associated with internal
penetrating and/or stricturing behaviour in the pediatric
CD population [16].
Clear association of anti-OmpC antibodies with IBD,
especially CD and complicated forms of CD highlights
contribution of large intestinal microbiota to the etio-
pathogenesis of IBD. If the dysbiosis as a trigger of IBD
pathogenesis could be influenced, we would be able to
combat these diseases more successfully [25-27].
Anti-GP2 antibodies are aimed at GP2, which are spe-
cific receptors present not only in the exocrine pancreas,
but also on microfold cells of intestinal Peyer’s patches,
which are believed to be the hotbed of CD inflammation
[28]. Association between anti-GP2 antibodies and CD
has already been described [28-32] and we have con-
firmed the relationship between both, anti-GP2 IgG,
anti-GP2 IgA with CD. Our patients with UC showed no
difference in neither anti-GP2 IgG nor in anti-GP2 IgA
from healthy controls, which is in agreement with data
provided by Bogdanos et al. [32].
Higher prevalence of anti-GP2 antibodies in patients
with complicated forms of CD has been postulated re-
cently. Bogdanos et al. [32] revealed the association be-
tween anti-GP2 IgG with stricturing behaviour (B2) and
perianal disease in CD patients. An extensive Hungarian
study, which included 579 CD patients, confirmed the
relationship of pancreatic antibodies with penetrating(B3) phenotype and perianal disease [31]. Our results
are in close agreement with the Hungarian study:
serum anti-GP2 IgA antibodies in our CD patients with
B2 + B3 and B3 phenotype were characterised by
significantly higher levels than in CD patients with B1
behaviour. We also found a trend towards statistically
significant difference in anti-GP2 IgG between B1 and
B2 + B3 phenotype.
Association between pancreatic antibodies and extra-
intestinal manifestation of CD was described by Lakatos
et al. [31] and we also have confirmed higher levels of
anti-GP2 IgA in CD patients, who have had an extrain-
testinal manifestation of the disease, however no statisti-
cally significant difference was noted.
According to the localisation of GP2 receptors in the
small bowel Pavlidis et al. assumed anti-GP2 seroposi-
tivity in patients with ileal/ileocolonic CD, what he also
confirmed [33]. On the contrary, we did not find any
significant differences in anti-GP2 IgA and anti-GP2
IgG depending on disease location in our CD patients,
however, the number of patients included might not be
robust enough to draw any firm conclusions in this
case.
The need of immunosupresive therapy in our patients
(corticosteroids +/− methotrexate +/− azathioprine +/−
biological therapy) was associted with higher levels of
anti-GP2 IgA.
The serological markers, anti-OmpC and anti-GP2 anti-
bodies, may aid us in diagnosing accurately the patients
who have developed complicated forms of CD. By utilising
these markers in clinical practice this could facilitate and
guide us in forming tailored treatment plans for our
patients.Conclusions
Association of anti-OmpC IgA with CD and UC was
confirmed. Positivity of anti-OmpC IgA is more frequent
in CD compared to UC.
CD patients with stricturing (B2) and stricturing +
penetrating (B2 + B3) phenotype had significantly higher
levels of anti-OmpC IgA compared to patients with
nonstricturing-nonpenetrating (B1) phenotype.
Association between the need of surgery in CD patients
and higher levels of anti-OmpC antibodies was revealed.
Relationship of anti-GP2 IgA and anti-GP2 IgG with
CD but not with UC was found out.
CD patients with penetrating (B3) and stricturing +
penetrating (B2 + B3) phenotype had significantly higher
levels of anti-GP2 IgA compared to patients with B1
phenotype.
In CD higher levels of anti-GP2 IgA antibodies were
found in patients with extraintestinal manifestation and
in those who needed immunosuppressive therapy.
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